Skin disease in organ transplantation /

Skin disease is a serious long-term problem for the recipients of solid organ transplants. The potent systemic immunosuppression therapy necessary to sustain a life-saving solid organ transplant is associated with many adverse cutaneous effects, including significantly increased rates of cutaneous m...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Otley, Clark C., 1964-
Formato: Electrónico eBook
Idioma:Inglés
Publicado: New York : Cambridge University Press, 2008.
Temas:
Skin > Diseases > Etiology.
Immunosuppressive agents > Side effects.
Transplantation of organs, tissues, etc.
Skin Diseases > etiology
Immunosuppressive Agents > adverse effects
Immunosuppressive Agents > therapeutic use
Organ Transplantation
Skin Diseases > diagnosis
Skin Diseases > therapy
Peau > Maladies > Étiologie.
Immunosuppresseurs > Effets secondaires.
Greffe (Chirurgie)
HEALTH & FITNESS > Diseases > Skin.
MEDICAL > Dermatology.
Skin > Diseases > Etiology
Hautkrankheit
Transplantation
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Cover; Half-title; Title; Copyright; Dedication; Contents; List of Contributors; Foreword
  • Transplant Dermatology: Skin Disease in Organ Transplant Recipients; Foreword
  • ''Life is a Matter of Balance''; Foreword; Preface; Acknowledgments; Section One TRANSPLANT DERMATOLOGY: AN EVOLVING DYNAMIC FIELD; 1 Introduction to Transplant Dermatology; INTRODUCTION TO TRANSPLANT DERMATOLOGY; SOLID ORGAN TRANSPLANTATION AND SKIN CANCER; HISTORY OF TRANSPLANT DERMATOLOGY; ORGANIZATIONS IN TRANSPLANT DERMATOLOGY; THE CHALLENGE; REFERENCES; Section Two TRANSPLANT MEDICINE AND DERMATOLOGY.
  • 2 The History of Organ TransplantationREFERENCES; 3 The Development of Modern Immunosuppressive Medications; INTRODUCTION; OVERALL STRATEGY FOR SOLID ORGAN TRANSPLANT IMMUNOSUPPRESSION; TODAY
  • CURRENT IMMUNOSUPPRESSION; Corticosteroids; Antiproliferative Agents
  • Azathioprine and Mycophenolate; Calcineurin Inhibitors
  • Cyclosporine and Tacrolimus; mTOR Inhibitors
  • Sirolimus and Everolimus; Biological Agents; OKT3; Thymoglobulin and Other Polyclonal Anti-Lymphocyte Antibodies; Alemtuzumab (Campath-1H); Anti-Interleukin-2 Receptor (CD25) Antibodies
  • Basiliximab and Daclizumab.
  • TOMORROW
  • THE PIPELINESUMMARY; REFERENCES; 4 Organ Transplantation: Current Status and Practice; OVERVIEW OF THE CURRENT STATUS OF SOLID ORGAN TRANSPLANTATION; RECENT TRENDS IN SOLID ORGAN TRANSPLANT NUMBERS AND SURVIVAL RATES; RECENT DEVELOPMENTS IN SOLID ORGAN TRANSPLANT PRACTICE; THE FUTURE OF SOLID ORGAN TRANSPLANTATION; REFERENCES; 5 The Immunology of Transplantation and Allograft Rejection; OVERVIEW OF THE DEVELOPMENT AND CURRENT STATUS OF TRANSPLANT IMMUNOLOGY; THE INNATE IMMUNE AXIS; Localized Release of Proinflammatory Mediators; Transplant-Specific Considerations.
  • Recruitment of Inflammatory Cell PopulationsTransplant-Specific Considerations; Uptake of Antigenic Material and Maturation of Antigen Presenting Cells; Transplant-Specific Considerations; COGNATE CELLULAR IMMUNITY
  • THE DENDRITIC CELL/T-CELL AXIS; The Major Histocompatibility Complex (MHC) and Antigen Presentation to T-cells; Transplant-Specific Considerations; T-cell Costimulation; Transplant-Specific Considerations; T-cell Differentiation, Effector Function and Memory; Transplant-Specific Considerations; COGNATE HUMORAL IMMUNITY
  • THE B-CELL/ANTIBODY/COMPLEMENT AXIS.
  • Primary B-Cell Responses and B-Cell MemoryNatural Antibodies; Antibody Effector Functions; Transplant-Specific Considerations; IMMUNOLOGICAL TOLERANCE; Central T-Cell Tolerance; Peripheral T-Cell Tolerance; B-Cell Tolerance; SUMMARY; REFERENCES; 6 Allograft-Specific Considerations in Transplant Dermatology; KIDNEY; Patient Demographics; Population; Age; Recipient Ethnicity; Gender; Effect of End Organ Disease on Skin Cancer Incidence; Overall Effect on Skin Cancer/Skin Disease; Alternative Therapies; Donor Population; Immunogenicity of Allografts; Immunosuppressive Regimens.

Ejemplares similares